Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

16Citations
Citations of this article
85Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients' progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling.

Cite

CITATION STYLE

APA

Mateo, L., Duran-Frigola, M., Gris-Oliver, A., Palafox, M., Scaltriti, M., Razavi, P., … Aloy, P. (2020). Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine, 12(1). https://doi.org/10.1186/s13073-020-00774-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free